Imperial College London

DrClaireFletcher

Faculty of MedicineDepartment of Surgery & Cancer

Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 2821claire.fletcher07 CV

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Summary

Post-Doctoral Career Development Fellow and Prostate Cancer Foundation Young Investigator.

My principal research interests lie in the field of small RNA and post-transcriptional regulation of gene expression in human disease. Specifically, I am interested in the mechanisms through which microRNAs ‘fine tune’ gene regulation, and how aberrations in these networks may contribute to disease. I am particularly intrigued by the regulatory mechanisms that govern microRNA biosynthesis, and by the huge potential of microRNA inhibitors/mimics to act as novel therapeutics in a wide array of conditions. Further interests include: microRNA ‘signatures’ as diagnostic or prognostic biomarkers, microRNA: long non-coding RNA (lncRNA) interaction networks, regulation of gene activity through alternative polyadenylation and RNA modifications, exosomal RNA-mediated communication mechanisms, and interplay between non-coding RNAs, nuclear receptors and DNA damage in cancer.

Ongoing projects:

  1.  Delineating Mechanisms of Post-Transcriptional Regulation of Wild-Type and Variant Androgen Receptors in Prostate Cancer for Therapeutic Intervention
  2. Exosomal Communication Between Peri-Prostatic Adipocytes and Epithelial Cells in Obesity-Driven Prostate Cancer
  3.  Kinase Modulators of MicroRNA Biogenesis
  4.  Apoptosis-modulating microRNA:target networks in drug-sensitive and -resistant breast cancer
  5.  Systematic Identification of MicroRNA Drivers of Resistance to Novel Therapeutics in Advanced Prostate Cancer – Exploitation as Stratification Biomarkers and Drug Targets
  6.   Functional Characterisation of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer
  7. MiR-346: lncRNA interactions link Androgen Receptor activity and DNA repair
  8.  Non-invasive microRNA signatures for predicting chemotherapy response in metastatic castration-resistant prostate cancer.

Publications:

  • Fletcher CE, Sulpice E, Coombe S, Guyon L, Hamilton M, Chrysostomou S, Leach D, Sharp A, Welti J, Yuan W, Dart DA, International SU2C/PCF Prostate Cancer Dream Team, Swain A, Lupold S, De Bono JS, McGuire SE, Gidrol X and Bevan C (2018). A Novel High-Throughput Screening Approach Identifies Androgen Receptor-Modulatory MicroRNAs and New Therapeutic Targets in Prostate Cancer  (submitted)
  • Fletcher CE (2017). AR-v7 liquid biopsy for treatment stratification in prostate cancer: how close are we? Current Opinion in Urology 27(5):500-509
  • Fletcher CE, Godfrey JD, Shibakawa A, Bushell M and Bevan CL (2017). A Novel Role for GSK3β as a Modulator of Drosha Microprocessor Activity and MicroRNA Biogenesis. Nucleic Acids Res. Mar 17; 45(5): 2809–2828
  • Fletcher CE, Dart DA and Bevan CL (2014): Interplay between Steroid Hormones and MicroRNAs: Implications for Hormone-Dependent Cancers. Endocrine-Related Cancer 21(5): R409-429.
  • Sita-Lumsden A#, Fletcher CE#, Dart DA, Brooke GN, Waxman J, Bevan CL (2013). Circulating nucleic acids as biomarkers of prostate cancer. Biomarkers in Medicine 7(6): 867-877. (# - joint first authors)
  • Frampton AE, Fletcher CE, Gall TMH, Krell J, Castellano L, Bevan CL, Stebbing J (2013): Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer. Expert Review Molecular Diagnostics 13(5): 425-430
  • Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie P and Bevan CL (2012): Androgen-regulated processing of the oncomir, miR-27a, which targets Prohibitin in prostate cancer. Hum. Mol. Genet. 21(14):3112-27.

 

Book Chapter:

  • Bevan CL, Fletcher CE, Sita-Lumsden A and Shibakawa A (2015, in press). Chapter 28: Circulating Nucleic Acids as Prostate Cancer Biomarkers. In: Garcia-Giménez JL ed. Epigenetic Biomarkers and Diagnostics. Elsevier.

 

Publications

Journals

Fletcher C, Orafidiya F, Deng L, et al., 2022, Crosstalk between long non coding RNAs, microRNAs and DNA damage repair in prostate cancer: new therapeutic opportunities?, Cancers, ISSN:2072-6694

Eringyte I, Zamarbide Losada JN, Powell SM, et al., 2020, Coordinated AR and microRNA regulation in prostate cancer, Asian Journal of Urology, Vol:7, ISSN:2214-3882, Pages:233-250

Fletcher CE, 2019, The Role of Splicing Regulators in the Emergence of Treatment-induced Neuroendocrine Prostate Cancer: The Next Generation of Drug Targets?, European Urology, Vol:76, ISSN:0302-2838, Pages:167-169

Fletcher C, Sulpice E, Combe S, et al., 2019, Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer, Oncogene, Vol:38, ISSN:0950-9232, Pages:5700-5724

Fletcher CE, 2017, AR-v7 liquid biopsy for treatment stratification in prostate cancer: how close are we?, Current Opinion in Urology, ISSN:0963-0643

More Publications